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Introduction
Currently, the combination of several active substances 
with different mechanisms of action in a single drug pre-
sented interest in medical practice [1-3]. In recent years, 
combinations of medicinal substances have been developed 
for different purposes, such as achieving synergism, reduc-
ing antibiotic resistance, reducing side effects, lower prices 
and increasing the treatment compliance [2, 3]. Currently, 
there is an interest in local combination therapy in der-
matology [4]. There are already multiple combinations of 
antibiotics, topical corticosteroids, local anesthetics for 
external use [4-6]. However, the biggest challenge of der-
matological drug combinations remains the simultaneous 
treatment of antibiotic-resistant bacterial infections and 
skin diseases [7].
In recent years, the development of antibiotic resistance 
has led to use antibacterial drugs, such as nitrofuran de-
rivatives [8]. Researchers have also focused on modernizing 
the chemical structure of existing antibacterial substances 
to obtain new, less toxic molecules [9]. A similar problem 
was resolved by obtaining isohydrafural (isonicotinoyl hy-
drazone of 5-nitro-2-furan aldehyde) by a group of resear-
chers from the Republic for Moldova [9, 10]. It has signifi-
cant bactericidal activity in concentrations between 1.25- 
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Abstract
Background: The isohydrafural and fluocinolone acetonide combined ointment contributes to the diversification of the treatment of dermatitis and 
psoriasis associated with bacterial infections. Complex stability studies were performed to ensure the quality of it during the shelf life. The objective of 
this study was to determine the stability and shelf life of the combined ointment containing isohydrafural and fluocinolone acetonide.
Material and methods: Three series of ointment were tested by the real-time method (temperature 25± 2°C; relative humidity 60 ± 5%) over a period 
of 30 months, periodically determining the appearance, homogeneity, pH, viscosity, identity, purity and assay. OHAUS DV215 CD electronic balance, 
Shimadzu LC-20 A HPLC, Consort C861 pH meter and Fungilab rheometer were used to fulfil the study. 
Results: At 24 months after storage, the three series of the ointment proved to be homogeneous, with a pH between 5.76 and 5.53. The rheograms showed 
a pseudoplastic behavior, with a slight thixotropy, with a viscosity close to 70 cP. The active substances were detected at the characteristic retention times: 
isohydrafural – 3 minutes, fluocinolone acetonide – 5.9 minutes and also no additional peaks occurred. The content of active substances was within the 
permitted limits: 0.098-0.11% (m/m) for isohydrafural and 0.0248-0.025% (m/m) for fluocinolone acetonide.
Conclusions: The combined ointment containing isohydrafural and fluocinolone acetonide was found to be stable under the storage conditions stipulated 
in the quality specification. The established shelf life is 24 months.
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5.0 μg/ml, of all investigated strains of Staphylococcus genus 
[9, 10]. Isohydrafural is also less toxic (LD50=990 mg/kg) than 
nitrofural (LD50=166.7 mg/kg) and effective for topical ap-
plication [9, 10]. Fluocinolone acetonide is a topical gluco-
corticoid, used in various dermatological diseases, such as 
dermatitis, psoriasis, lupus erythematosus etc. It has already 
existed in combined dosage forms, mixed with neomycin 
sulphate [11]. The combination of isohydrafural and fluo-
cinolone acetonide in the same ointment dosage form, con-
tributes to the diversification of the treatment of dermatitis 
and psoriasis associated with bacterial infections. 
Stability of a drug is an important indicator of physical, 
chemical, therapeutical and microbiological safety. For the 
semisolid dosage forms the most important causes of insta-
bility are the chemical interactions and also the conferring 
by the excipients of a favorable environment for bacteria 
growth [12-14]. Stability studies are performed to prevent 
or eliminate these undesired causes. Stability studies are re-
quired in the process of developing a new drug before the 
elaboration of Analytical and Standardization Documents 
in order to establish its shelf life [12-14]. For semisolid der-
matological dosage forms, such as ointment, the ICH guide-
line recommends determining the stability and shelf life by 
real-time (long-term) method, which consists in analysis of 
the quality parameters corresponding to the dosage form at 
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certain time intervals, by storage at temperature 25±2°C and 
relative humidity 60±5% [12]. According to the ICH guide-
line, the shelf life is considered to be established when there 
has been a decrease in the concentration of active substan-
ces of 90% [12-14].
The combined ointment containing isohydrafural and 
fluocinolone acetonide was elaborated within the research 
laboratories of Nicolae Testemitanu State University of 
Medicine and Pharmacy. Complex stability studies are nec-
essary to ensure the quality of the combined ointment con-
taining isohydrafural and fluocinolone acetonide during its 
shelf life. As a consequence, the objective of this study was to 
determine the stability and shelf life of the combined oint-
ment containing isohydrafural and fluocinolone acetonide.
Material and methods
Ointment preparation. The pure substances, isohy-
drafural, (synthesized at the Department of Organic 
Chemistry, Chisinau State University of Moldova, concen-
tration 99.9%) and fluocinolone acetonide (Sigma Aldrich, 
99.9% concentration) were used. The excipients: propylene 
glycol, cetostearyl alcohol and petroleum jelly were used ac-
cording to specifications of pharmacopoeia. All other mate-
rials were of analytical grade. Extemporaneous preparation 
of ointment was done by heating 3.0 g cetostearyl alcohol at 
50-550C, cooling at 350C and then adding 91.875 g of petro-
leum jelly with stirring (lipophilic phase). Then 0.025 g of 
fluocinolone acetonide was dissolved in 5.0 g of propylene 
glycol and the obtained solution with 0.1 g of isohydrafural 
was added to lipophilic phase with stirring. The ointment 
was transferred to a suitable dark glass container.
Stability studies and shelf life determination. According 
to ICH Harmonised Tripartite Guideline Topic Q1C, 3 series 
of ointment were tested by the real-time method (tempera-
ture 25± 2°C; relative humidity 60±5%) over a period of 30 
months, periodically determining the appearance, homoge-
neity, pH, viscosity, identity, purity and assay [12-14].
Appearance and homogeneity were tested by visual ob-
servation. pH measurement was determined by using the 
pH meter Consort C861 and the solution prepared by dis-
solving 1.0 g of ointment in 25 ml of deionized water and 
heating at 370C, cooling at room temperature and then fil-
tering. The measurements were carried out in triplicate.
Rheological behavior was tested by using Rotational 
Viscometer Multi Visc Rheometer, Fungilab (Spain). The 
viscosity was analyzed at a fix shear rate of 3 rpm at 20±20C, 
which is a typical determination for ointments [12, 14]. The 
rheograms of shear stress as a function of shear rate during 
the period of 30 months of storage at 20±20C were recorded 
in order to determine the rheological behavior of the com-
bined ointment.
Identity, purity and assay of isohydrafural and fluo-
cinolone acetonide from the ointment were performed by 
HPLC method, which has been previously developed and 
validated. For chromatographic separation, the Shimadzu 
HIGH Performance liquid chromatograph LC-20 A and 
Nucleosil C18 chromatographic column, with dimensions 
5x300 mm, particle size 2.6 μm were used. The mixture of 
acetonitrile and purified water in the ratio 40:60 was select-
ed as the mobile phase. UV-VIS detection was performed at 
a wavelength of 260 nm. The flow rate of the mobile phase 
was 0.4 ml/minute. The temperature of the chromatograph-
ic column was maintained at 30°C.
Preparation of the isohydrafural standard solution: 0.05 g 
(exact mass) of isohydrafural standard was transferred into 
a 50 ml volumetric flask, then 20 ml of mobile phase was 
added and stirred until the substance dissolved. Then it was 
made up to the mark with mobile phase. Further 1 ml was 
transferred into a 10 ml volumetric flask and was made up 
to the mark with mobile phase.
Preparation of the fluocinolone acetonide standard solu-
tion: 0.05 g (exact mass) of fluocinolone acetonide standard 
was transferred into a 100 ml volumetric flask, then 30 ml of 
mobile phase was added and stirred until the substance dis-
solved. Then it was made up to the mark with mobile phase. 
Further 0.5 ml was transferred into a 10 ml volumetric flask 
and was made up to the mark with mobile phase.
Preparation of the sample solution: about 2.5 g of ointment 
was accurately weighed and transferred into a porcelain 
cup, to which 10 ml of mobile phase was added and heated 
in a water bath at 30°C until the ointment was melted. The 
sample was allowed to cool at room temperature and was 
filtered and collected into a 25 ml volumetric flask. The 
extraction was repeated twice with each 5 ml mobile phase. 
The obtained samples were added to the first extraction 
solution and were made up to the mark with mobile phase. 
The concentration of isohydrafural in the combined 
ointment was calculated by the formula 1.
     
      
Ax · 25 · mst 
Ast · mx · 50 · 10
· P,X =
        in which:      (1)
X – the content of isohydrafural in the ointment, g;
Ax – the area of the isohydrafural peak from the chroma-
togram of the sample solution;
Ast – the area of the isohydrafural peak from the chroma-
togram of the standard solution;
mx – the amount of ointment taken for analysis, g;
mst – the amount of isohydrafural standard, g;
P – total ointment mass, g.
The concentration of fluocinolone acetonide in the com-
bined ointment was calculated by the formula 2.
                     Ax · 25 · mst · 0.5
Ast · mx · 100 · 10
· P,X =        in which:     (2)
X – the content of fluocinolone acetonide in the oint-
ment, g;
Ax – the area of the fluocinolone acetonide peak from the 
chromatogram of the sample solution;
Ast – the area of the fluocinolone acetonide peak from the 
chromatogram of the standard solution;
mx – the amount of ointment taken for analysis, g;
mst – the amount of fluocinolone acetonide standard, g;
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P – total ointment mass, g.
For measurements was used OHAUS DV215 CD 
electronic balance.
The shelf life of the combined ointment was determined 
in months and was based on a limit of 10% degradation of 
active substances in accordance with the recommendations 
of ICH guideline [12, 13, 14]. 
Statistical analysis. All values were reported as mean ± 
standard deviation. Statistical measurements were carried 
out by using the Statistical Package for the Social Sciences 
(IBM SPSS Statistics) 10.5 software.
Results and discussion
The stability studies of the combined ointment contain-
ing isohydrafural and fluocinolone acetonide were investi-
gated to improve its quality and to predict the period of its 
stable storage [14].
Appearance and homogeneity. Appearance and homo-
geneity are very important parameters for the stability stu-
dies, the appropriate characteristics contributing to easier 
packaging and application on the skin, while any noticeable 
change shows the degradation of the drug [12-14].
Determinations made on the day of preparation showed 
that the combined ointment containing isohydrafural and 
fluocinolone acetonide was smooth, yellow, odorless and 
homogeneous. During 24 months, the combined ointment 
showed no change in appearance. At 30 months after storage, 
an intensification of the color and loss of homogeneity were 
observed.
pH measurement. pH is a quality parameter necessary to 
be studied in determining the stability of a dermatological 
drug, indicating its compatibility with the pH of the skin. 
The deviation from the limits (between 4.0 and 6.0) indicates 
the degradation of the drug [12-14].
For the combined ointment, pH values were recorded 
compatible with skin application  over the period of 30 













Fig. 1.  The pH values of the isohydrafural and fluocinolone 
acetonide combined ointment
Rheological behavior. In the process of developing a 
new ointment it is essential to create an optimal viscosity 
by determining the amounts of viscosity enhancer at the 
preformulation and formulation stages of the drug, in order 
to prevent further instability. For the combined ointment 
containing isohydrafural and fluocinolone acetonide, the 
cetostearyl alcohol excipient was used as an enhancer, its 
amount being determined to provide an optimal viscosity 
close to 70 cP [12, 14]. A significant change of the ointment 
viscosity value in the stability study process is a reliable 
indication of drug degradation [12-14]. During the period 
of 30 months the viscosity values of all three batches of the 
combined ointment were close to 70 cP, being compatible 
for application on the skin (tab. 1).
Table 1
The viscosity values of the isohydrafural and 
fluocinolone acetonide combined ointment




(mean±standard deviation, 3 determinations)
Batch 1 Batch 2 Batch 3
0 73.5±0.6 73.8±0.5 73.1±0.1
3 71.0±0.1 71.0±0.2 71.0±0.1
6 70.5±0.4 70.2±0.1 70.2±0.1
9 69.7±0.1 69.9±0.1 69.9±0.1
12 69.1±0.1 69.1±0.1 69.1±0.1
18 68.9±0.1 68.9±0.1 68.9±0.1
24 68.2±0.1 68.2±0.1 68.2±0.1
30 69.4±0.2 71.1±0.1 71.1±0.1
The rheograms of shear stress as a function of shear rate 
during the period of 30 months of storage at 20±20C, in-
dicate that the combined ointment showed a non-Newto-
nian, pseudoplastic, characteristic for ointments behavior, 
although a slight decrease in values was observed (fig. 2.1, 
2.2., 2.3).
 
Fig. 2.1. The rheograms of batch 1 of the isohydrafural and 
fluocinolone acetonide combined ointment
Identity and purity. Identity and purity quality parameters 
demonstrate that no degradation products have appeared as 
a result of hydrolysis, oxidation, reduction, decomposition 
etc. of active substances and excipients [12-14].
The chromatograms of the three batches of the combined 
ointment corresponded to the quality parameters identity 
and purity during the period of 24 months, both active 
substances being detected, while the retention time values 
were included within the permissible limits: isohydrafural 
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– 3 minutes, fluocinolone acetonide – 5.9 minutes. At 30 
months after storage, there were changes of the retention 
time values specific to fluocinolone acetonide, indicating its 
degradation (tab. 2).
Table 2
The retention time values of active substances  






Batch 1 Batch 2 Batch 3
IHF FLAc IHF FLAc IHF FLAc
0 3.112 5.997 3.112 5.996 3.112 5.997
3 3.110 5.995 3.112 5.998 3.112 5.996
6 3.112 5.997 3.113 5.997 3.111 5.998
9 3.113 5.997 3.112 5.998 3.112 5.994
12 3.112 5.996 3.110 5.997 3.112 5.997
18 3.111 5.998 3.112 5.997 3.111 5.998
24 3.110 6.011 3.111 6.014 3.110 5.998
30 2.897 6.277 2.877 6.401 2.884 6.371
Note: IHF – isohydrafural; FLAc – fluocinolone acetonide.
Assay. Assay analysis of the dosage form is essential, 
because a change of the concentration of active substance 
can influence the efficacy of the drug. Also, the drug can be 
considered unstable if it retained less than 90% of in initial 
concentration of active substance [12-14].
During the period of 24 months, both active substances 
were detected on the chromatograms of all three series of the 
combined ointment in concentrations within the permitted 
limits: 0.098 – 0.110 g/100 g ointment for isohydrafural 
and 0.0248 – 0.0250 g/100 g ointment for fluocinolone 
acetonide. At 30 months after storage, the concentration of 
fluocinolone acetonide was below 0.0248 g/100 g ointment, 
indicating its degradation (tab. 3).
The stability profile curves of all three batches of the 
combined ointment, obtained by the real-time method, 
indicate a reducing up to 90% of fluocinolone acetonide 
concentration at 30 months of testing, that undergoes faster 
degradation than isohydrafural (fig. 3.1, 3.2, 3.3).
Table 3
The content of active substances of the isohydrafural  




Content, g/100 g ointment
Batch 1 Batch 2 Batch 3
IHF FLAc IHF FLAc IHF FLAc
0 0.10013 0.02504 0.10001 0.02501 0.09996 0.02500
3 0.09996 0.02500 0.09992 0.02499 0.09988 0.02498
6 0.09984 0.02498 0.09985 0.02498 0.09978 0.02497
9 0.09976 0.02495 0.09975 0.02496 0.09965 0.02494
12 0.09960 0.02493 0.09960 0.02493 0.09965 0.02492
18 0.09946 0.02492 0.09949 0.02491 0.09954 0.02491
24 0.09932 0.02490 0.09936 0.02488 0.09943 0.02490
30 0.09872 0.02268 0.09905 0.02267 0.09915 0.02262
Note: IHF – isohydrafural; FLAc – fluocinolone acetonide.
Fig. 3.1. Stability profile curves of batch 1 of the isohydrafural 
and fluocinolone acetonide combined ointment
Shelf life. The results of stability testing of the combined 
ointment containing isohydrafural and fluocinolone ac-
etonide indicate a shelf life of 24 months at temperature 
25±2°C and relative humidity 60±5%, time required for 
fluocinolone acetonide concentration to reduce up to 90%. 
During 24 months of real-time testing, the combined oint-
ment presented no physical instability and underwent no 
significant changes of pH, viscosity, retention time and con-
centration of the active substances, the values being within 
the admissible limits (tab. 4).
 Fig. 2.2. The rheograms of batch 2 of the isohydrafural and 
fluocinoloneacetonide combined ointment
Fig. 2.3. The rheograms of batch 3 of the isohydrafural and 
fluocinolone acetonide combined ointment
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Fig. 3.2. Stability profile curves of batch 2 of the isohydrafural 
and fluocinolone acetonide combined ointment
Fig. 3.3. Stability profile curves of batch 3 of the isohydrafural 
and fluocinolone acetonide combined ointment
Table 4

































0 Corresponds 5.76±0.01 Corresponds Corresponds 0.10013 0.02504
3 Corresponds 5.75±0.01 Corresponds Corresponds 0.09996 0.02500
6 Corresponds 5.73±0.01 Corresponds Corresponds 0.09984 0.02498
9 Corresponds 5.71±0.01 Corresponds Corresponds 0.09976 0.02495
12 Corresponds 5.68±0.01 Corresponds Corresponds 0.09960 0.02493
18 Corresponds 5.63±0.01 Corresponds Corresponds 0.09946 0.02492
24 Corresponds 5.53±0.02 Corresponds Corresponds 0.09932 0.02490
30 Does not correspond 5.37±0.01 Corresponds Does not correspond 0.09872 0.02268
Batch 2
0 Corresponds 5.77±0.02 Corresponds Corresponds 0.10001 0.02501
3 Corresponds 5.75±0.01 Corresponds Corresponds 0.09992 0.02499
6 Corresponds 5.72±0.01 Corresponds Corresponds 0.09985 0.02498
9 Corresponds 5.71±0.01 Corresponds Corresponds 0.09975 0.02496
12 Corresponds 5.67±0.01 Corresponds Corresponds 0.09960 0.02493
18 Corresponds 5.63±0.01 Corresponds Corresponds 0.09949 0.02491
24 Corresponds 5.53±0.01 Corresponds Corresponds 0.09936 0.02488
30 Does not correspond 5.41±0.1 Corresponds Does not correspond 0.09905 0.02267
Batch 3
0 Corresponds 5.77±0.01 Corresponds Corresponds 0.09996 0.02500
3 Corresponds 5.74±0.01 Corresponds Corresponds 0.09988 0.02498
6 Corresponds 5.73±0.01 Corresponds Corresponds 0.09978 0.02497
9 Corresponds 5.70±0.01 Corresponds Corresponds 0.09965 0.02494
12 Corresponds 5.67±0.01 Corresponds Corresponds 0.09965 0.02492
18 Corresponds 5.62±0.01 Corresponds Corresponds 0.09954 0.02491
24 Corresponds 5.53±0.01 Corresponds Corresponds 0.09943 0.02490
30 Does not correspond 5.29±0.01 Corresponds Does not correspond 0.09915 0.02262
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Conclusions
The results of stability testing of the combined oint-
ment containing isohydrafural and fluocinolone acetonide, 
obtained by the real-time method, indicate that until 24 
months the dosage form maintained its quality parameters, 
while at 30 months after storage, an intensification of the 
color, loss of homogeneity were observed and also inap-
propriate values of identity, purity and assay were recorded. 
The stability profile curves indicate that during the testing 
period isohydrafural is more stable in combined ointment 
than fluocinolone acetonide, which concentration reduced 
up to 90% at 30 months of storage.
The stability studies, performed by the real-time meth-
od, also allowed to determine the shelf life of the combined 
ointment at room temperature (25±2°C) and a relative hu-
midity of 60±5%, which is 24 months. Therefore, it is rec-
ommended that the combined ointment containing isohy-
drafural and fluocinolone acetonide should be kept in cool 
place, protected from light in a dark container made from 
physically and chemically inert material that meets the 
pharmacopoeial standards.
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